Can "Inoperable" Congenital Heart Defects Become Operable in Patients with Pulmonary Arterial Hypertension? Dream or Reality?

被引：52

作者：

Beghetti, Maurice ^{[1
]}

Galie, Nazzareno ^{[2
]}

Bonnet, Damien ^{[3
]}

机构：

[1] Childrens Univ Hosp, Dept Child & Adolescent, Pediat Cardiol Unit, Geneva, Switzerland

[2] Univ Bologna, Inst Cardiol, Bologna, Italy

[3] Univ Paris 05, Necker Hosp, French Reference Ctr Complex Congenital Heart Dis, Paris, France

来源：

CONGENITAL HEART DISEASE | 2012年 / 7卷 / 01期

关键词：

Pulmonary Arterial Hypertension; Congenital Heart Defects; Bosentan; Sildenafil Nitrate; Prostacyclin; ATRIAL SEPTAL-DEFECT; CONTINUOUS INTRAVENOUS EPOPROSTENOL; ENDOTHELIN-RECEPTOR ANTAGONIST; PATENT DUCTUS-ARTERIOSUS; EISENMENGER-SYNDROME; BOSENTAN THERAPY; VASCULAR-RESISTANCE; DOUBLE-BLIND; DISEASE; REPAIR;

D O I：

10.1111/j.1747-0803.2011.00611.x

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The decision whether to repair congenital heart defects in patients with raised pulmonary vascular resistance to alleviate pulmonary hypertension is a complex one. The degree of pulmonary vascular disease is of paramount importance. Operating on patients with pulmonary vascular resistance above a certain threshold runs the risk of postoperative persistent pulmonary hypertension and a worse long-term prognosis. This review focuses on patients deemed borderline inoperable or inoperable due to pulmonary vascular disease and asks whether they can be converted to an operable status with pulmonary arterial hypertension-specific drugs that potentially modify the pulmonary vascular lesions and resistance.

引用

页码：3 / 11

页数：9

共 35 条

[1] Outcomes in patients with pulmonary hypertension undergoing percutaneous atrial septal defect closure [J].

Balint, O. H. ;

Samman, A. ;

Haberer, K. ;

Tobe, L. ;

McLaughlin, P. ;

Siu, S. C. ;

Horlick, E. ;

Granton, J. ;

Silversides, C. K. .

HEART, 2008, 94 (09) :1189-1193

[2] A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension [J].

Barst, RJ ;

Rubin, LJ ;

Long, WA ;

McGoon, MD ;

Rich, S ;

Badesch, DB ;

Groves, BM ;

Tapson, VF ;

Bourge, RC ;

Brundage, BH ;

Koerner, SK ;

Langleben, D ;

Keller, CA ;

Murali, S ;

Uretsky, BF ;

Clayton, LM ;

Jobsis, MM ;

Blackburn, SD ;

Shortino, D ;

Crow, JW .

NEW ENGLAND JOURNAL OF MEDICINE, 1996, 334 (05) :296-301

[3] Atrial septal defects versus ventricular septal defects in BREATHE-5, a placebo-controlled study of pulmonary arterial hypertension related to Eisenmenger's syndrome: A subgroup analysis [J].

Berger, Rolf M. F. ;

Beghetti, Maurice ;

Galie, Nazzareno ;

Gatzoulis, Michael A. ;

Granton, John ;

Lauer, Andrea ;

Chiossi, Eleonora ;

Landzberg, Michael .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2010, 144 (03) :373-378

[4] Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study [J].

Channick, RN ;

Simonneau, G ;

Sitbon, O ;

Robbins, IM ;

Frost, A ;

Tapson, VF ;

Badesch, DB ;

Roux, S ;

Rainisio, M ;

Bodin, F ;

Rubin, LJ .

LANCET, 2001, 358 (9288) :1119-1123

[5] Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy [J].

Dimopoulos, Konstantinos ;

Peset, Ana ;

Gatzoulis, Michael A. .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2008, 129 (02) :163-171

[6] Pulmonary arterial hypertension in congenital heart disease: An epidemiologic perspective from a Dutch registry [J].

Duffels, M. G. J. ;

Engelfriet, P. M. ;

Berger, R. M. F. ;

van Loon, R. L. E. ;

Hoendermis, E. ;

Vriend, J. W. J. ;

van der Velde, E. T. ;

Bresser, P. ;

Mulder, B. J. M. .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2007, 120 (02) :198-204

[7]

Eicken Andreas, 2007, Int J Cardiol, V117, pe40, DOI 10.1016/j.ijcard.2006.10.023

[8] IS LUNG-BIOPSY USEFUL FOR SURGICAL DECISION-MAKING IN CONGENITAL HEART-DISEASE [J].

FRESCURA, C ;

THIENE, G ;

GAGLIARDI, MG ;

MAZZUCCO, A ;

PELLEGRINO, PA ;

DALIENTO, L ;

BISCAGLIA, S ;

CARMINATI, M ;

GALLUCCI, V .

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1991, 5 (03) :118-123

[9] Reversal of pulmonary hypertension and subsequent repair of atrial septal defect after treatment with continuous intravenous epoprostenol [J].

Frost, AE ;

Quiñones, MA ;

Zoghbi, WA ;

Noon, GP .

JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2005, 24 (04) :501-503

[10] Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study):: a double-blind, randomised controlled trial [J].

Galie, N. ;

Rubin, L. J. ;

Hoeper, M. M. ;

Jansa, P. ;

Al-Hiti, H. ;

Meyer, G. M. B. ;

Chiossi, E. ;

Kusic-Pajic, A. ;

Simonneau, G. .

LANCET, 2008, 371 (9630) :2093-2100

← 1 2 3 4 →